S8 Ep3: Rethinking HER2: A Pan-Cancer Look at IHC, ERBB2, and Tumor-Agnostic Testing
HER2 has long been synonymous with breast cancer, but a growing body of evidence shows it's expressed, at some level, across nearly every solid tumor type. In this episode of Targeted Talks, host Sabrina Serani sits down with Dr Aditya Shreenivas (City of Hope National Medical Center) and Dr Razelle Kurzrock (Medical College of Wisconsin Cancer Center) to unpack their new real-world analysis, published in ESMO Open, using data made available by Caris Life Sciences, examining HER2 immunohistochemistry (IHC) expression and ERBB2 alterations across more than 200,000 tumors.
The conversation…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.